Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125876161 | 12587616 | 1 | I | 201510 | 20160713 | 20160725 | 20160725 | EXP | US-GLAXOSMITHKLINE-US2016100710 | GLAXOSMITHKLINE | 28.00 | YR | F | Y | 0.00000 | 20160725 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125876161 | 12587616 | 1 | PS | LAMICTAL | LAMOTRIGINE | 1 | Oral | 150 MG, QD | 20241 | 150 | MG | TABLET | QD | ||||||
| 125876161 | 12587616 | 2 | SS | LAMICTAL | LAMOTRIGINE | 1 | Oral | 300 MG, QD | 20241 | 300 | MG | TABLET | QD | ||||||
| 125876161 | 12587616 | 3 | SS | LAMOTRIGINE. | LAMOTRIGINE | 1 | Oral | U | 0 | 300 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125876161 | 12587616 | 1 | Seizure |
| 125876161 | 12587616 | 3 | Seizure |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125876161 | 12587616 | Exposure during pregnancy | |
| 125876161 | 12587616 | Live birth | |
| 125876161 | 12587616 | Rash |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125876161 | 12587616 | 1 | 2010 | 0 | ||
| 125876161 | 12587616 | 3 | 201512 | 0 |